Vertex Ventures Israel and Grove Ventures Capital Ltd have co-led a $5-million seed round in Nucleai Ltd, a Tel Aviv-based startup that uses artificial intelligence and machine learning algorithms to detect cancer and other diseases.
In a statement posted on its social media page, Nucleai confirmed the $5-million funding round, which was also joined by private investors Brian Cooper, founder of Retalix, and serial entrepreneur Nir Kalkstein, co-founder of Final and Medial Early Sign.
